Bdenza - a drug for the treatment of prostate cancer at a late stage. It is used to treat metastatic, castration-resistant prostate cancer, which is not amenable to surgical or drug therapy aimed at reducing testosterone levels.
The main active ingredient of the drug is Enzalutamide (enzalutamide) - a synthetic nonsteroidal anti-androgen, which blocks the body's ability to use any sex hormones.

Prostate cancer is formed in the gland of the male reproductive system, which is located below the bladder and in front of the rectum. In the cells of the prostate gland there are receptors that are associated with androgens - male sex hormones that help the growth of these cells. In the event of a tumor, its growth is stimulated by the main male sex hormone - testosterone, as well as related hormones.
By reducing the number of androgens, it is possible to reduce the cancer and slow its growth. The drug Kstandi (Xtandi®) refers to preparations group of anti-androgen, which act by preventing the action of sex hormones, including testosterone, and reduce the growth potential of prostate cancer cells.